UK markets close in 7 hours 21 minutes

Sumitomo Dainippon Pharma Co., Ltd. (DPM.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
2.2200-0.0200 (-0.89%)
As of 08:05AM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 887.79M
Enterprise value 3.10B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.45
Price/book (mrq)0.43
Enterprise value/revenue 0.01
Enterprise value/EBITDA -0.03

Trading information

Stock price history

Beta (5Y monthly) 0.59
52-week change 3-56.67%
S&P500 52-week change 321.33%
52-week high 35.5000
52-week low 32.0400
50-day moving average 32.3304
200-day moving average 32.8189

Share statistics

Avg vol (3-month) 350
Avg vol (10-day) 3N/A
Shares outstanding 5397.29M
Implied shares outstanding 6403.62M
Float 8179.4M
% held by insiders 157.59%
% held by institutions 116.56%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.09
Forward annual dividend yield 43.73%
Trailing annual dividend rate 37.00
Trailing annual dividend yield 3312.50%
5-year average dividend yield 42.25
Payout ratio 487.75%
Dividend date 3N/A
Ex-dividend date 430 Mar 2023
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in JPY.

Fiscal year

Fiscal year ends 31 Mar 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -52.59%
Operating margin (ttm)-37.93%

Management effectiveness

Return on assets (ttm)-11.64%
Return on equity (ttm)-34.90%

Income statement

Revenue (ttm)330.31B
Revenue per share (ttm)831.40
Quarterly revenue growth (yoy)-41.60%
Gross profit (ttm)N/A
EBITDA -188.88B
Net income avi to common (ttm)-173.72B
Diluted EPS (ttm)-2.6200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)42.81B
Total cash per share (mrq)107.75
Total debt (mrq)411.84B
Total debt/equity (mrq)119.86%
Current ratio (mrq)0.63
Book value per share (mrq)864.73

Cash flow statement

Operating cash flow (ttm)-275.33B
Levered free cash flow (ttm)-152.23B